{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:48:44Z","timestamp":1794325724456,"version":"4.9.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clinthera.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T16:24:07Z","timestamp":1541175847000},"page":"2170-2179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study"],"prefix":"10.1016","volume":"40","author":[{"given":"Hitoshi","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kobayashi-Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaya","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erina","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Yamasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yakushijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.10.004_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jchromb.2018.07.042","article-title":"FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine","volume":"1095","author":"Locatelli","year":"2018","journal-title":"J\u00a0Chromatogr B"},{"key":"10.1016\/j.clinthera.2018.10.004_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national Surgical adjuvant breast and Bowel Project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"For the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2018.10.004_bib4","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","article-title":"Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary","volume":"21","author":"Takeuchi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib6","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of clinical oncology clinical practice guideline Update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib7","series-title":"Antiemesis. Version 2. NCCN Clinical Practice Guidelines in Oncology","year":"2018"},{"key":"10.1016\/j.clinthera.2018.10.004_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting","volume":"25","author":"Einhorn","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2018.10.004_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib12","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib13","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"Schwartzberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2018.10.004_bib17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving Adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2018.10.004_bib18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2018.10.004_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2018.10.004_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician's choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2018.10.004_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2018.10.004_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1248\/bpb.b14-00745","article-title":"Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats","volume":"38","author":"Machida","year":"2015","journal-title":"Biol Pharm Bull"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818304958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818304958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T15:19:17Z","timestamp":1548775157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818304958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0149291818304958"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-related Risk Factors for Nausea and Vomiting with Standard Antiemetics in Patients with Breast Cancer Receiving Anthracycline-based Chemotherapy: A Retrospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}